ABBV | 3.60% | 191.48 | +0.14% | 727 | |
AZN | 3.36% | 11,392.0 | +2.10% | 979 | |
BMY | 3.25% | 46.87 | +0.02% | 2,256 | |
VRTX | 3.16% | 471.49 | +0.66% | 276 | |
LLY | 3.08% | 776.92 | +1.83% | 158 | |
ROG | 3.04% | 260.70 | +0.46% | 392 | |
NOVN | 2.81% | 95.20 | +0.51% | 1,077 | |
PFE | 2.81% | 24.21 | -0.37% | 4,696 | |
JNJ | 2.78% | 168.26 | +0.09% | 711 | |
SASY | 2.73% | 85.43 | -0.49% | 1,049 |
As of April 4, 2025, CI Bio-Revolution Index ETF has been acquired by CI Global Healthcare Leaders Index ETF. CI Bio-Revolution Index ETF is an exchange traded fund launched and managed by CI Global Asset Management. The fund invests in public equity markets of global region. It invests in stocks of companies operating across healthcare, pharmaceuticals, biotechnology, life sciences and genomics sectors. The fund invests in growth and value stocks of companies across diversified market capitalization. It seeks to track the performance of the Solactive Global Genomics Immunology and Medical Revolution CAD Hedged Index NTR, by using full replication technique. CI Bio-Revolution Index ETF was formed on February 24, 2022 and is domiciled in Canada.